Real-world safety and efficacy of lomitapide in homozygous familial hypercholesterolemia: interim report of special-use survey in Japan

References

• Nohara A , TadaH , OguraMet al. Homozygous familial hypercholesterolemia. J. Atheroscler. Thromb.28, 665–678 (2021).
   PubMed Web of Science ®Google Scholar
• Harada-Shiba M , AraiH , OhmuraHet al. Guidelines for the diagnosis and treatment of adult familial hypercholesterolemia 2022. J. Atheroscler. Thromb.30, 558–586 (2023).
   PubMed Web of Science ®Google Scholar
• Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies . 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis290, 140–205 (2019).
   PubMed Web of Science ®Google Scholar
• Cuchel M , RaalFJ , HegeleRAet al. 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance. Eur. Heart J.44(25), 2277–2291 (2023).
   PubMed Web of Science ®Google Scholar
• Alonso R , CuevasA , MataP. Lomitapide: a review of its clinical use, efficacy, and tolerability. Core Evid.14, 19–30 (2019).
   PubMed Web of Science ®Google Scholar
• Cuchel M , BloedonLT , SzaparyPOet al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N. Engl. J. Med.356(2), 148–156 (2007).
   PubMed Web of Science ®Google Scholar
• Cuchel M , MeagherEA , duToitet al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolemia: a single-arm, open-label, phase III study. Lancet381, 40–46 (2013).
   PubMed Web of Science ®Google Scholar
• Blom DJ , AvernaMR , MeagherEAet al. Long-term efficacy and safety of the microsomal triglyceride transfer protein inhibitor lomitapide in patients with homozygous familial hypercholesterolemia. Circulation136(3), 332–335 (2017).
   PubMed Web of Science ®Google Scholar
• D’Erasmo L , StewardK , CefalùABet al. Italian and European Working Group on Lomitapide in HoFH . Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the pan-European retrospective observational study. Eur. J. Prev. Cardiol.29(5), 832–841 (2022).
   PubMed Web of Science ®Google Scholar
• D’Erasmo L , GalloA , CefalùABet al. Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey. Orphanet. J. Rare Dis.16, 1 (381).
   PubMed Web of Science ®Google Scholar
• D’Erasmo L , CefalùAB , NotoDet al. Efficacy of lomitapide in the treatment of familial homozygous hypercholesterolemia: results of a real-world clinical experience in Italy. Adv. Ther.34(5), 1200–1210 (2017).
   PubMed Web of Science ®Google Scholar
• Kolovou G , DiakoumakouO , KolovouVet al. Microsomal triglyceride transfer protein inhibitor (lomitapide) efficacy in the treatment of patients with homozygous familial hypercholesterolaemia. Eur. J. Prev. Cardiol.27(2), 157–165 (2020).
   PubMed Web of Science ®Google Scholar
• Stefanutti C , MorozziC , DiGiacomo S , SovranoB , MesceD , GrossiA. Management of homozygous familial hypercholesterolemia in real-world clinical practice: a report of 7 Italian patients treated in Rome with lomitapide and lipoprotein apheresis. J. Clin. Lipidol.10(4), 782–789 (2016).
   PubMed Web of Science ®Google Scholar
• Ben-Omran T , MasanaL , KolovouGet al. Real-world outcomes with lomitapide use in paediatric patients with homozygous familial hypercholesterolaemia. Adv. Ther.36(7), 1786–1811 (2019).
   PubMed Web of Science ®Google Scholar
• Taubel J , SumerayM , LorchU , McLeanA. Pharmacokinetics and pharmacodynamics of lomitapide in Japanese subjects. J. Atheroscler. Thromb.23(5), 606–620 (2016).
   PubMed Web of Science ®Google Scholar
• Harada-Shiba M , IkewakiK , NoharaAet al. Efficacy and safety of lomitapide in Japanese patients with homozygous familial hypercholesterolemia. J. Atheroscler. Thromb.24, 402–411 (2017).
   PubMed Web of Science ®Google Scholar
• Nohara A , OtsuboY , YanagiKet al. Safety and efficacy of lomitapide in Japanese patients with homozygous familial hypercholesterolemia (HoFH): results from the AEGR-733-301 long-term extension study. J. Atheroscler. Thromb.26(4), 368–377 (2019).
   PubMed Web of Science ®Google Scholar
• Stefanutti C . Lomitapide-a microsomal triglyceride transfer protein inhibitor for homozygous familial hypercholesterolemia. Curr. Atheroscler. Rep.22(8), 38 (2020).
   PubMed Web of Science ®Google Scholar
• Takeji Y , TadaH , OguraMet al. Committee on Primary Dyslipidemia under the Research Program on Rare and Intractable Disease of the Ministry of Health, Labor, and Welfare of Japan . Clinical characteristics of homozygous familial hypercholesterolemia in Japan: a survey using a National Database. JACC Asia3(6), 881–891 (2023).
   PubMedGoogle Scholar
• Underberg JA , CannonCP , LarreyD , MakrisL , BlomD , PhillipsH. Long-term safety and efficacy of lomitapide in patients with homozygous familial hypercholesterolemia: five-year data from the Lomitapide Observational Worldwide Evaluation Registry (LOWER). J. Clin. Lipidol.14, 807–817 (2020).
   PubMed Web of Science ®Google Scholar
• Harada-Shiba M , KoezukaR , MakinoH , OguraM. Gradual dose titration of lomitapide may prevent therapeutic delays in patients with homozygous familial hypercholesterolemia. J. Atheroscler. Thromb.30, 203–205 (2023).
   PubMed Web of Science ®Google Scholar
• Raal FJ , RosensonRS , ReeskampLFet al. ELIPSE HoFH Investigators . Evinacumab for homozygous familial hypercholesterolemia. N. Engl. J. Med.383(8), 711–720 (2020).
   PubMed Web of Science ®Google Scholar